Corey A. Carter

3.3k total citations · 1 hit paper
56 papers, 2.2k citations indexed

About

Corey A. Carter is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Corey A. Carter has authored 56 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 18 papers in Molecular Biology. Recurrent topics in Corey A. Carter's work include Lung Cancer Research Studies (17 papers), Lung Cancer Treatments and Mutations (16 papers) and Neuroendocrine Tumor Research Advances (13 papers). Corey A. Carter is often cited by papers focused on Lung Cancer Research Studies (17 papers), Lung Cancer Treatments and Mutations (16 papers) and Neuroendocrine Tumor Research Advances (13 papers). Corey A. Carter collaborates with scholars based in United States, South Africa and Finland. Corey A. Carter's co-authors include Bryan Oronsky, Daniel Morgensztern, C. Patrick, Arnold L. Oronsky, Tony R. Reid, Giuseppe Giaccone, Jane B. Trepel, Christina Brzezniak, Scott Caroen and Arun Rajan and has published in prestigious journals such as Journal of Clinical Oncology, Biochemistry and Cancer Research.

In The Last Decade

Corey A. Carter

56 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas

2017 437 citations Bryan Oronsky, C. Patrick et al. Neoplasia profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Corey A. Carter United States	22	1.2k	642	616	545	443	56	2.2k
Antonia Martinetti Italy	32	1.5k 1.3×	685 1.1×	837 1.4×	618 1.1×	618 1.4×	121	2.8k
Ralf J. Rieker Germany	27	694 0.6×	738 1.1×	369 0.6×	485 0.9×	435 1.0×	91	2.2k
Joo Young Kim South Korea	21	932 0.8×	292 0.5×	598 1.0×	293 0.5×	357 0.8×	75	1.8k
Michela Del Prete Italy	25	857 0.7×	362 0.6×	539 0.9×	265 0.5×	369 0.8×	75	1.9k
Catherine Wheeler United States	30	1.7k 1.5×	1.1k 1.8×	254 0.4×	323 0.6×	520 1.2×	73	3.6k
Nils D. Arvold United States	26	1.3k 1.2×	605 0.9×	646 1.0×	359 0.7×	1.5k 3.5×	67	3.3k
Arlene Berman United States	22	1.3k 1.1×	614 1.0×	111 0.2×	438 0.8×	474 1.1×	47	2.4k
Serena Desideri United States	21	688 0.6×	922 1.4×	501 0.8×	272 0.5×	372 0.8×	69	2.7k
John Mandeli United States	24	659 0.6×	608 0.9×	287 0.5×	90 0.2×	310 0.7×	82	2.2k
Viktória László Hungary	29	715 0.6×	834 1.3×	335 0.5×	360 0.7×	581 1.3×	70	2.3k

Countries citing papers authored by Corey A. Carter

Since Specialization

Citations

This map shows the geographic impact of Corey A. Carter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Corey A. Carter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Corey A. Carter more than expected).

Fields of papers citing papers by Corey A. Carter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Corey A. Carter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Corey A. Carter. The network helps show where Corey A. Carter may publish in the future.

Co-authorship network of co-authors of Corey A. Carter

This figure shows the co-authorship network connecting the top 25 collaborators of Corey A. Carter. A scholar is included among the top collaborators of Corey A. Carter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Corey A. Carter. Corey A. Carter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lin, Jie, Derek W. Brown, Stephanie Shao, et al.. (2021). Comparative study of survival among small cell lung cancer patients in the U.S. military health system and those in the surveillance, epidemiology, and end results (SEER) program. Annals of Epidemiology. 64. 132–139. 3 indexed citations

Oronsky, Bryan, Tony R. Reid, Christopher Larson, et al.. (2019). REPLATINUM Phase III Randomized Study: RRx-001 + Platinum Doublet Versus Platinum Doublet in Third-Line Small Cell Lung Cancer. Future Oncology. 15(30). 3427–3433. 47 indexed citations

Oronsky, Bryan, Tony R. Reid, Arnold L. Oronsky, & Corey A. Carter. (2017). What's New in SCLC? A Review. Neoplasia. 19(10). 842–847. 137 indexed citations

Oronsky, Bryan, C. Patrick, Daniel Morgensztern, & Corey A. Carter. (2017). Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia. 19(12). 991–1002. 437 indexed citations breakdown →

Oronsky, Bryan, Tony R. Reid, Christopher Larson, et al.. (2017). RRx-001 protects against cisplatin-induced toxicities. Journal of Cancer Research and Clinical Oncology. 143(9). 1671–1677. 19 indexed citations

Brzezniak, Christina, Bryan Oronsky, Jane B. Trepel, et al.. (2017). RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor. Case Reports in Oncology. 10(1). 276–280. 6 indexed citations

Lin, Jie, Katherine A. McGlynn, Corey A. Carter, et al.. (2016). The Impact of Preexisting Mental Health Disorders on the Diagnosis, Treatment, and Survival among Lung Cancer Patients in the U.S. Military Health System. Cancer Epidemiology Biomarkers & Prevention. 25(12). 1564–1571. 29 indexed citations

Carter, Corey A., Bryan Oronsky, Scott Caroen, et al.. (2016). Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets. Case Reports in Oncology. 9(2). 285–289. 8 indexed citations

Horn, Leora, Heather A. Wakelee, Karen L. Reckamp, et al.. (2016). MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC. Journal of Thoracic Oncology. 11(11). S256–S257. 7 indexed citations

10.

Carter, Corey A., Paul Peterson, Mary Quinn, et al.. (2016). Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. Case Reports in Oncology. 9(1). 164–170. 12 indexed citations

11.

Kim, Michelle M., Hemant Parmar, Yue Cao, et al.. (2016). Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial. Translational Oncology. 9(2). 108–113. 27 indexed citations

12.

Reckamp, Karen L., Jeffrey R. Infante, George R. Blumenschein, et al.. (2016). Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 11(2). S36–S37. 8 indexed citations

13.

Carter, Corey A., Bryan Oronsky, Jan Scicinski, et al.. (2015). Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor. Case Reports in Oncology. 8(3). 461–465. 11 indexed citations

14.

Thomas, Anish, Arun Rajan, Arlene Berman, et al.. (2015). Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. The Lancet Oncology. 16(2). 177–186. 197 indexed citations

15.

Reid, Tony, Bryan Oronsky, Jan Scicinski, et al.. (2015). Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. The Lancet Oncology. 16(9). 1133–1142. 76 indexed citations

16.

Carter, Corey A., Scott Caroen, Arnold L. Oronsky, & Bryan Oronsky. (2015). Dysphonia after Bevacizumab Rechallenge: A Case Report. Case Reports in Oncology. 8(3). 423–425. 7 indexed citations

17.

Thomas, Anish, Arun Rajan, Éva Szabó, et al.. (2014). A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study. Clinical Cancer Research. 20(21). 5392–5402. 79 indexed citations

18.

Carter, Corey A., et al.. (2014). Molecular Targets in the Treatment of Non—Small-Cell Lung Cancer: Is There Hope on the Horizon?. Postgraduate Medicine. 126(7). 139–148. 2 indexed citations

19.

Rajan, Arun, Corey A. Carter, Arlene Berman, et al.. (2014). Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. The Lancet Oncology. 15(2). 191–200. 99 indexed citations

20.

Rajan, Arun, Corey A. Carter, Ronan J. Kelly, et al.. (2012). A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors. Clinical Cancer Research. 18(8). 2344–2351. 125 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact